Recently, four independent papers reported unexpected autoimmune phenotypes such as multi-organ inflammation, including the stomach, and ataxia in full-body Malt1-PD mice (4–6, 47), which could indicate a risk when inhibiting MALT1 protease activity for therapeutic reasons. This evidence concerns the gene MALT1 and Ataxia.